Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Firy Inc. (FIRY) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

Firy Inc. vs Novavax Inc — how do they compare? Firy Inc. trades at $11.73 (market cap $199.80M), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 9.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Novavax Inc for 59 Days on average.

FIRYNVAX
Market Cap
$199.80M$1.82B
Volume
92,9936,198,505
Sector
TechnologyHealth
52-Week High
$13.10$12.56
52-Week Low
$2.28$6.22
Typical Hold Time
13 Days59 Days
Enterprise Value
$168.40M$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Firy Inc.

FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, showing continued volatility amid its transition to a holding company structure. The stock maintains a bullish technical signal despite negative profitability metrics, with revenue stabilizing around $100M annually but net losses persisting. Recent developments include a $719M legal victory against Papaya Gaming and board additions, though cash burn remains elevated at -$86M in 2025.

The outlook remains speculative with significant execution risk. While the legal win provides potential upside, persistent losses and cash burn challenge near-term viability. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty around the company's ability to monetize assets and achieve profitability.

Novavax Inc

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIRY
0% Buy100% Sell
Avg holding period · 13 Days
NVAX
59% Buy41% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Firy Inc.

Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.

Read more on FIRY →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →